Dual-Targeting FAPI-RGD Compound for Tumor Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for tumors are limited by the inability to effectively target both fibroblast activation protein (FAP) and integrin αvβ3 simultaneously, which are both overexpressed in various tumor types.
Innovation Solution
Development of a dual-targeting compound with an FAPI-RGD structure that can simultaneously bind to FAP and integrin αvβ3, enhancing tumor uptake and detection efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate targeting agents for FAP and integrin αvβ3 are used, then each target can be addressed individually, but the overall tumor uptake efficiency and detection efficiency are limited
Solution Approach 1:
The patent combines FAPI and RGD moieties into a single dual-targeting compound structure, merging two separate targeting functions (FAP binding and integrin αvβ3 binding) into one molecule. This eliminates the need for multiple separate agents while simultaneously achieving dual targeting, thereby improving tumor uptake efficiency without proportionally increasing complexity
Solution Approach 2:
The dual-targeting compound serves multiple functions simultaneously: it binds to both FAP and integrin αvβ3 receptors, enabling the single agent to target multiple tumor-associated markers. This multi-functionality approach allows one compound to replace what would traditionally require separate targeting agents, improving overall detection and treatment efficiency
2Productivity
If a single compound targets both FAP and integrin αvβ3, then tumor uptake efficiency is improved, but the molecular structure becomes more complex
Solution Approach 1:
The dual-targeting compound is constructed as a composite molecular structure combining FAPI (fibroblast activation protein inhibitor) and RGD (arginine-glycine-aspartic acid) moieties. This composite approach integrates two distinct functional units into one molecule, enabling simultaneous binding to FAP and integrin αvβ3 while maintaining reasonable structural complexity through modular design
Solution Approach 2:
The compound exhibits local functional differentiation with distinct regions: the FAPI portion specifically targets FAP while the RGD portion specifically targets integrin αvβ3. This local quality approach allows different parts of the molecule to perform specialized functions, achieving high detection efficiency through targeted binding at multiple sites without requiring the entire molecule to be overly complex
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dual-targeting compound improves the number and utilization efficiency of effective receptors in tumors, leading to enhanced tumor uptake and detection efficiency in diagnostic imaging and potential therapeutic applications.
Implementation Method 1
the dual-targeting compound can simultaneously target FAP and integrin αvβ3... containing a specific binding ligand structure of both FAP and integrin αvβ3
Data Source
AI summary
The present invention relates to a dual-targeting compound capable of targeting fibroblast activation protein (FAP) and integrin αvβ. The targeting compound of the present invention and a radionuclide marker thereof can synergistically target an FAP target and an integrin αvβ3 target in tumors, such that the number and utilization efficiency of effective receptors in tumors can be improved. The present invention further provides a radionuclide marker based on the targeting compound, a preparation method therefor and use thereof in diagnosis or treatment of diseases characterized by overexpression of fibroblast activation protein (FAP) and/or integrin αvβ3.